D. Western Therapeutics Institute, Inc. announced that it expects to receive ¥6.344 million in funding from SMBC Nikko Securities Inc., Investment Arm
July 21, 2020
Share
D. Western Therapeutics Institute, Inc. (JASDAQ:4576) announced a private placement of 52,000 stock acquisition right at the price of ¥122 per right for gross proceeds of ¥6,344,000 on July 22, 2020. The transaction will include participation from SMBC Nikko Securities Inc., Investment Arm through third party allotment. There are 100 shares per stock acquisition right. The initial exercise price is ¥410. There is no maximum exercise price. The minimum exercise price is ¥287. Akasaka International Accounting Co., Ltd calculated the price.
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Companyâs drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
D. WESTERN THERAPEUTICS INSTITUTE, INC. 